Darifenacin Tablet, Film Coated, Extended Release
Product Images NDC 16571-768

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 16571-768). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Darifenacin Fig1)

This appears to be a graph or chart showing two lines labeled "75mgod" and "15mgod" with the X-axis labeled as "Time Post-Dose (Hours)" and the Y-axis labeled as "WL g\g\q I 1" and markers at 0, 4, 8, 12, 16, 20, and 24 hours. Without further context or information, it is not possible to provide a useful description.*

FDA Label Image

Figure 2a. Median Change From Baseline At Weeks 2, 6, 12 For Number Of Urge Incontinence Episodes Per Week (study 1) (Darifenacin Fig2)

The text describes a figure labeled as "Figure 2a, Study 1" that shows the median reduction in incontinence episodes per week over a period of 12 weeks. The graph shows three different lines representing the placebo and two different doses of Darifenacin (7.5 mg and 15 mg) with their corresponding symbols. The numbers 6 and 12 are also mentioned, potentially indicating time periods or data points on the graph.*

FDA Label Image

Figures 2b. Median Change From Baseline At Weeks 2, 6, 12 For Number Of Urge Incontinence Episodes Per Week (study 2) (Darifenacin Fig3)

The text describes a chart or figure titled "Figure 2b, Study 2" that displays the median reduction (and 95% Cl) in incontinence episodes/week from baseline over a period of 2, 6, and 12 weeks for three treatments: placebo, darifenacin 7.5 mg, and darifenacin 15 mg.*

FDA Label Image

Figures 2c. Median Change From Baseline At Weeks 2, 6, 12 For Number Of Urge Incontinence Episodes Per Week (study 3) (Darifenacin Fig4)

This text is a description of a figure in a study labeled as Study 3. The figure is labeled as Figure 2c, and it shows data related to a treatment or intervention over a period of 8 weeks. There are two treatment groups, one labeled as "Placebo" and the other labeled as "Darifenacin 15 mg." The rest of the text is not readable due to incorrect detection, so a thorough description of the study results cannot be provided.*

FDA Label Image

Package Label-principal Display Panel (7.5 mg (30 Tablet Bottle))

FDA Label Image

Package Label-principal Display Panel- 15 mg (30 Tablet Bottle) (Darifenacin Fig6)

Each Darifenacin tablet made by Rising Pharma Holdings, Inc. contains 17.85 mg of hydrobromide equivalent to 15 mg of darifenacin. It is an extended-release tablet that should not be chewed, cut, or crushed. The usual dosage is one tablet per day, and it has to be stored at 20° to 25°C (68° to 77°F) protected from light. The packaging contains 30 tablets, and it is distributed by Made In India. The product identification code is NDC16571-768-03.*

FDA Label Image

Chemical Structure (Darifenacin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.